Revive Therapeutics Ltd.
RVV
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.28% | 40.94% | -267.12% | 71.03% | 54.01% |
| Total Depreciation and Amortization | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -56.34% | 1,454.76% | 307.26% | -36.22% | -75.60% |
| Change in Net Operating Assets | 65.78% | 1,536.00% | 4,261.54% | 388.61% | 187.41% |
| Cash from Operations | 96.27% | 69.99% | 97.87% | 95.75% | 76.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | 100.00% | -- |
| Cash from Investing | -- | -- | -100.00% | 100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 43.05% | -100.00% | -100.00% |
| Cash from Financing | -- | -- | 35.96% | -96.97% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.27% | 101.25% | 88.61% | -102.49% | 76.07% |